Drug Trial Radar · NCT06081348
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Sep 16, 2024
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Holland Bloorview Kids Rehabilitation HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Azrieli Foundation (Funder); Canadian Institutes of Health Research (Funder); Ontario Brain Institute (Funder); McMaster University; Western University; Queen's University; University of Alberta; Alberta Health services; St. Justine's Hospital; Dalhousie University; Unity Health Toronto; University of Toronto; The Hospital for Sick Children; Maternal, Infant, Child and Youth Research Network (MICYRN)
- First posted
- Oct 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 8 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.
Conditions
- Neurodevelopmental Disorders
- Autism
- Autism Spectrum Disorder
- Fragile X Syndrome
- Tuberous Sclerosis
- 22Q11 Deletion Syndrome
- 22Q11 Deletion
- ADHD
- Tic Disorders
- Tourette Syndrome
- Tourette Syndrome in Children
- Tourette Syndrome in Adolescence
- ADHD - Combined Type
- ADHD Predominantly Inattentive Type
- ADHD, Predominantly Hyperactive - Impulsive
- Anxiety
- Anxiety Disorders
Interventions
SertralineDrug
Oral capsule (25mg, 50mg, 100mg, 200mg)
PlaceboOther
Oral placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Screen for Child Anxiety Related Emotional Disorders (SCARED) - parent versionTime frame: 16 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Alberta Children's Hospital - University of Calgary
Calgary, Alberta, Canada · Recruiting
University of Alberta-Glenrose
Edmonton, Alberta, Canada · Recruiting
Dalhousie University - IWK Health Centre
Halifax, Nova Scotia, Canada · Active not recruiting
McMaster University
Hamilton, Ontario, Canada · Recruiting
Queen's University
Kingston, Ontario, Canada · Recruiting
University of Western Ontario, Lawson Health Research Institute
London, Ontario, Canada · Recruiting
Holland Bloorview Kids Rehabilitation Hospital
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.